Latest News & Announcements
Stay up to date with the latest news, announcements, and scientific advancements from Kite. Discover our research breakthroughs and company updates.
Recent News & Announcements
Stay informed about our latest developments, research breakthroughs, and company updates
FDA Approves Label Update for Yescarta®
Kite announced that the FDA has approved a label update for Yescarta® for the treatment of adult patients with relapsed or refractory primary central nervous system lymphoma (PCNSL).
Kite Presents New Data at ASH
Kite presented new clinical and real-world data at the American Society of Hematology (ASH) Annual Meeting, highlighting the continued impact of its CAR T-cell therapies.
Next-Generation CAR T Therapies Show Promise
Kite announced early-phase results from its next-generation CAR T-cell therapy programs, including KITE-753 and KITE-363, showing encouraging response rates.
Gilead to Acquire Arcellx
Gilead Sciences announced plans to acquire Arcellx to strengthen its cell therapy portfolio and support the development of anito-cel for multiple myeloma.
Manufacturing Expansion Announced
Kite announced the expansion of its cell therapy manufacturing capabilities to support growing demand and improve patient access.
iMMagine-1 Study Results
Kite announced results from the iMMagine-1 study evaluating anito-cel in patients with relapsed or refractory multiple myeloma.
Media Inquiries
For press inquiries and media requests, please contact our communications team
Email: media@kitepharma.com
Phone: +1 (555) 123-4567